

## Medicinal properties of macrofungi

Dorota Hilszczańska

Forest Research Institute, Department of Forest Ecology, ul. Braci Leśnej 3, Sękocin Stary, 05–090 Raszyn, Poland.

✉ Tel. +48 22 7150502, fax. +48 22 7150504, e-mail: d.hilszczanska@ibles.waw.pl

**Abstract.** This review highlights the importance to people of some types of wild fungi considered in the context of non-wood forest products. Macrofungi are used both for food and medicine purposes. Substances isolated from the higher Basidiomycetes and Ascomycetes mushrooms express promising immune modulating, antitumor, antiviral, antibacterial and antidiabetic properties. They have been, and are presently, used against cancer in some countries in Far East as well as in the United States of America and Canada. Their useful properties are mainly conferred by biologically-active polysaccharides present in the fruiting bodies and cultured mycelium. A few dozen different polysaccharide antitumor agents have been developed from such species as: *Ganoderma lucidum*, *Lentinus edodes*, *Schizophyllum commune*, *Trametes versicolor* and *Inonotus obliquus*. In the review some other fungi and their properties are also described. The information is provided to widen our knowledge of the importance of the organisms that live in forest ecosystems.

**Key words:** fungal polysaccharides, medicinal mushrooms, antitumor activities

### 1. Introduction

Medicinal properties of macrofungi (mainly belonging to Basidiomycota) have been known for ages and used. In folk medicine (Hobbs 1995; Wasser, Weis 1999), history of using many different types of fungal extracts demonstrating immunostimulatory, anti-inflammatory and anticancer activity dates back to ancient Japan, China and other countries from the Far East. In many developed countries (United States of America, Israel), scientific achievements from these regions are used to implement complementary therapeutic methods (Wasser 2002).

Some of the best known substances present in fungi showing pharmacological properties (especially anticancer and immunological) are polysaccharides (Ooi, Liu 2000; Wasser 2002; Mordali et al. 2007; Zhang et al. 2007). Polysaccharides or polysaccharide–protein complexes present in fungi have gained the attention of researchers because it is believed that they can inhibit

tumour growth enhancing the organism's abilities to defend itself. They are often called as host's defensive potential or biological response modifiers (Leung et al. 2006; Moradali et al. 2007).

Furthermore, these biomacromolecules have the ability of preventing carcinogenesis and tumours metastasis (Guterres et al. 2005; Lee et al. 2005). The mechanism of anticancer influence of polysaccharides is still not fully understood, but what has been found is that they can activate immune cells. They stimulate lymphocyte and macrophage division and synthesis of cytokines (including interleukins, interferons and immunoglobulins directed against cancers antigens) (Wasser 2002; Mordali et al. 2007).

In the 1970s and 1980s, a few anticancer polysaccharides were isolated. These were: lentinian, schizophyllan and polysaccharide–protein complexes (PSK, PSP) obtained from *Lentinus edodes*, *Schizophyllum commune* and *Trametes versicolor* that are very popular in the Far East countries (Mizuno et al. 1995; Ooi et Liu 2000). Widely used as diet and therapy

supplements, aiding cancer treatment were also PD-glucans present in *Grifola frondosa*, *Sparassis crispa*, *Agaricus blazei* or *Phellinus linteus*. Many reviews dedicated to issues related to anticancer properties of polysaccharides, esp. isolation, biological activity, have been written in the past decade.

The aim of this work is to show the present state of knowledge about fungi polysaccharides used in medicine, mainly in treating cancer.

## 2. Anticancer compounds present in fungi

These fungi are considered as macrofungi that have a clear, visible carpophores. Taxonomically they belong to classes Basidiomycetes and Ascomycetes, but the majority belong to the former. The knowledge about the real number of macrofungi is still incomplete. Hawksworth (2001) reports that the number is between 14.000 and 22.000. It is estimated that 2000 species can be eaten without harm to health; 700 have scientifically proven medical properties (Wasser 2002). Fungi are a vast and still not fully used source of new applications in pharmacology and medicine, mostly because of the presence of polysaccharides with immunostimulatory and anticancer properties. Biologically active polysaccharides can be found not only in pericarps, but also in mycelium (pure culture), sclerotes or filtrates (Cheung 2008). Many fungi polysaccharides are found in the form of glucans with different type of glycosid connections; some are real heteroglicans while others are still connected to proteins (Ooi, Liu 2000). Fungal polysaccharides with anticancer properties seem to be connected to the cell wall, built of chitin, cellulose (1→3, 1→6)-β-glucans and (1→3)-α-glucans or polysaccharide–protein complexes such as: galactomannan protein and glucuromannan protein (Zhang et al. 2007). However, anticancer properties were not found in chitin (Mizuno et al. 1995).

Due to the chemical structure, polysaccharides can be divided into homo- and heteroglucans. They are the largest group of polysaccharides with anticancer properties. They are supported by many heteroglicans and polysaccharide–protein complexes. In table 1, some isolated from vegetative mycelium or carpophores polysaccharides compounds with anticancer properties are shown.

Polysaccharides demonstrating antitumour activity differ significantly in terms of chemical structure and physical properties. Homopolimer compounds and complex heteropolimers have a wide range of activity.

However, it is extremely difficult to carry out the correlation between structure of polysaccharide and the effectiveness in combating sickness. It seems that a significant role in compound activity is played by a type of glycosides bonds (Bohn, BeMiller, 1995). Surenjav et al. (2006) think that β-glucans containing mainly bonds (1→6) have lower activity in combating cancer cells, similar to those of lower molecular weight. The observed natural inconstancy of anticancer polysaccharides and multiplicity of compounds with different chemical structure, such as heteroglicans and compounds heteroglican-protein, have caused that the issue of which structure of polysaccharide decides its anticancer activity is still unsolved.

## 3. Selected species and description of substances they include and which are used in medicine

Currently, among fungi used in oncology, the most popular are species belonging to the genus *Ganoderma*: *G. lucidum*, *G. tsugae*, *G. capense* and *G. applanatum*; they are also the best known medicinal fungi in the Far East (Cheung 2008). They contain a number of polysaccharides with anticancer properties: β-glucan, glucu-ronoglican, mannoglucan, other active heteroglicans as well as polysaccharide–protein complexes. Extract from *G. lucidum* which inhibits proliferation of cancer cells is used in the treatment of breast cancer. One of the glucans, marked as LZS-1, gained from spores of *G. lucidum* in experiments conducted on mice, was effective against sarcoma 180 and Lewis lung cancer (Jiang et al. 2004). Polysaccharide isolated from vegetative mycelium *G. lucidum* is the main ingredient of the drug given to animals (experimental phase) ailing from malignant fibroma. The same compound increases phagocytes activity in the human body (Lee et al. 2003).

Studies on the anticancer effect of substances present in *Lentinus edodes* began in the 1970s (Chihara et al. 1970). Isolated β-glucan, called as letinian, in *in vitro* studies did not show direct influence on cancer cells (Wasser 2002). Attempts of chemical modification of water-insoluble compound (α-(1→3)-D-glucan) to a hydrated sulphate proved to have a positive result, and the use of new compound resulted in inhibition of cancer cells proliferation in 52% patients with breast cancer (Zhang, Cheung 2002).

Schizophyllan isolated from *Schizophyllum commune* is similar to letinian in terms of chemical structure and

**Table 1.** Antitumour polysaccharides from fungi

Polysaccharide	Species of fungus	Literature
<b>Homoglucans</b>		
(1→6)-β-glucan	<i>Agaricus blazei</i> , <i>A. brasiliensis</i> , <i>Lyophyllum decastes</i> ,	Kobayashi et al., 2005; Camelini et al., 2005; Angeli et al., 2006; Ukawa et al., 2000;
(1→3)-β-glucan	<i>Agrocybe cylindracea</i> , <i>Amanita muscaria</i> , <i>Auricularia auricula</i> , <i>Collybia dryophila</i> , <i>Cordyceps sinensis</i> , <i>Flammulina velutipes</i> , <i>Ganoderma lucidum</i> , <i>Grifora frondosa</i> , <i>Heiricium erinaceus</i> , <i>Lentinus edodes</i> , <i>Phellinus linteus</i> , <i>Pleurotus ostreatus</i> , <i>Schizophyllum commune</i> , <i>Sparassis crispa</i>	Yoshida et al., 1996; Kiho et al., 1992; Misakiet Kakuta, 1995; Pacheco-Sanchez et al., 2006; Yalin et al., 2005; Smiderle et al., 2006; Han et al., 1995; Kodama et al., 2002; Dong et al., 2006; Surenjav et al., 2005; Kim et al., 1996; Carbonero et al., 2006; Ogawa and Kaburagi, 1982; Ohno et al., 2000;
β-glucan	<i>Trametes gibbona</i> , <i>Tylopilus felleus</i> , <i>Volvariell avolvacea</i>	Czarneckiet Grzybek, 1995; Grzybek et al., 1990; Kishida et al., 1989;
<b>Heteroglucans</b>		
Mannogalactoglucan	<i>Agaricus blazei</i> , <i>Fomitella fraxinea</i> , <i>Pleurotus cornucopiae</i> , <i>P. pulmonarius</i> ,	Cho et al., 1999; Cho et al., 1998; Gutierrez et al., 1996; Gutierrez et al., 1996;
Xsylo-galactoglucan	<i>Inonotus obliquus</i>	Mizuno et al., 1999;
Xsylo-glucan	<i>Pleurotus pulmonarius</i> , <i>Polyporus cnfluens</i>	Gutierrez et al., 1996; Mizuno et al., 1992;
Galacto-xyloglucan	<i>Hericium erinaceus</i>	Mizuno et al., 1992;
<b>Heteroglycans</b>		
Heterogalactan	<i>Agaricus bisporus</i> , <i>B. blazei</i> , <i>Flammulina velutipes</i> , <i>Pleurotus erynii</i> , <i>P. ostreatus</i>	Shidaet Sakai, 2004; Shidaet Sakai, 2004; Shidaet Sakai, 2004; Shidaet Sakai, 2004; Shidaet Sakai, 2004;
Fucogalactan	<i>Hericium erinaceus</i>	Shida et Sakai, 2004;
Glucogalactan	<i>Ganoderma tsugae</i> , <i>Hericium erinaceus</i>	Wangetal., 1993; Wang et al., 2004;
Galactomannan	<i>Collybia maculata</i>	Lim et al., 2005;
Mannogalactofucan	<i>Grifola frondosa</i>	Zhuang et al., 1994;

Polysaccharide	Species of fungus	Literature
<b>Polysaccharide–protein complex</b>		
(1→6)-β-D-glucan–protein	<i>Agaricus blazei</i>	Honget Choi, 2007;
(1→3)-β-glucan– protein	<i>Ganoderma tsuaga</i>	Wang et al., 1993;
Proteoglican	<i>Ganoderma lucidum</i> , <i>Pleurotus ostreatus</i>	Baek et al., 2002;
α-glucan– protein	<i>Tricholoma matsutake</i>	Hoshi et al., 2005;
Polysaccharide– protein	<i>Hebeloma crustuliniforme</i> , <i>Phellinus linteus</i> , <i>Tricholoma lobayense</i>	Choet Chung, 1999; Kim et al., 2006; Liu et al., 1996;
Heteroglican– protein	<i>Grifola frondosa</i> , <i>Pleurotus sajor-caju</i> , <i>Tremella fuciformis</i>	Zhuang et al., 1994; Zhuang et al., 1993; Cho et al., 2006.

biological activity as well as anticancer activity (Jong et al. 1991). Schizophyllan restores and increases cellular immunity in the ill organism by activating macrophages (Okazaki et al. 1995). Endopolysaccharide obtained from vegetative mycelium *Inonotus obliquus* works similarly (Kim et al. 2005).

In the case of (1→3)-β-glucans extracted from *Grifola frondosa*, direct cytotoxicity against prostate cancer cells was observed. The reduction of cancer cells was particularly high when polysaccharide was enriched with vitamin C (Konno et al. 2002).

α-Glucan, characterised by low molecular weight, isolated from *Pleurotus ostreatus*, has promising properties. This compound showed direct activity by inducing the cells responsible for killing cancer cells resulting in colorectal cancer (Lavi et al. 2006). However, the other heteropolysaccharide-protein complex obtained from fructification had a strong effect of inhibiting the development of leukaemia cancer cells (Wong et al. 2007).

Polysaccharide-protein compounds obtained from *Trametes versicolor* tested *in vitro* and *in vivo* showed direct or indirect cytotoxic activity, restricting the growth of cancer cells proliferation in case of leukaemia and breast cancer (Lau et al. 2004). The polysaccharide-protein complex marked as PSK turned out successful in inhibition of cell growth and DNA synthesis of various cancer types, i.e.: leukaemia, sarcoma, breast cancer and liver cancer (Tsukagoshi et al. 1984). Similarly, the compound marked as PSP (polysaccharide-peptide) proved to be

active in the inhibition of lung cancer cells, stomach cancer cells and skin cancer cells proliferation (Cui and Chisti 2003). The capability of polysaccharide-protein connections to stimulate the body's immune system to direct cytotoxic activity seems to result from their unique structural characteristics, protein particles and/or specific carbohydrate bindings (Ooi, Liu 2000).

#### 4. Summary

In the last few decades, much attention has been paid to the use of biological substances present in macrofungi in treating, compulsory therapy or as health diet aids. The most attention researchers give is to the possibility of their safe use in prevention and treatment of cancer. Biologically active polysaccharides in fungi can be mostly found in carpophores, mycelium, sclerota and filtrates. One of the most promising features of polysaccharide-protein compounds present in fungi is activity immunostimulating and anticancer. However, the mechanism of this activity is not yet well understood. The opinion that the mentioned compounds interact with the different immunological cells, which can cause cascade transduction of signals responsible for immunological system reaction, finds acceptance. Many from tested macromolecules can also directly interact with cancer cells, inhibiting the process of uncontrolled growth and binding cancer cells. It is possible that both types of activity can be complementary.

Immune-stimulating and anticancer properties of fungi polysaccharides are well described but there is a lack of full characteristics of compound activity at the cellular and molecular levels depending on its construction. The understanding of the process of recognition of fungi polysaccharides (especially  $\beta$ -glucan) by immunological cells receptors and transmitted signals activating would increase the possibilities of practical application of these compounds.

The practical use of medical compounds also requires development and availability of appropriate biotechnologies. The most common way to obtain a quality product is mycelial cultures kept on liquid media. This method allows reducing the fungi collection from natural environments as well as controlling the growth of mycelium.

Many mysteries of fungi have not yet been discovered, and the number of studies on acquisition from these new, valuable for medicine compounds still grows, as evidenced in many publications, including the scientific journal *International Journal of Medicinal Mushrooms*, dedicated to this topic.

## References

- Angeli J. P. F., Ribeiro L. R., Gonzaga M. L. C., Soares S. D., Ricardo M. P. S. N., Tsuboy M. S. et al. 2006. Protective effects of  $\beta$ -glucan extracted from *Agaricus brasiliensis* against chemically induced DNA damage in human lymphocytes. *Cell Biology and Toxicology*, 22: 285–291.
- Baek S. J., Kim Y. S., Yong H. M., Chae J. B., Lee S. A., Bae W. C. *Yakhak Hoeji*, 46: 11–17.
- Bohn J. A., BeMiller J. N. 1995. (1 $\rightarrow$ 3)- $\beta$ -D-Glucans as biological response modifiers: A review of structure-functional activity relationships. *Carbohydrate Polymers*, 28: 3–14.
- Camelini C. M., Maraschin M., de Mendonca M. M., Zucco C., Ferreira A. G., Tavares L. A. 2005. Structural characterization of  $\beta$ -glucans of *Agaricus brasiliensis* in different stages of fruiting body maturity and their use in nutraceutical products. *Biotechnology Letters*, 27: 1295–1299.
- Carbonero E. R., Gracher A. H. P., Smiderle F. R., Rosado F. R., Sasaki G. L., Gorin P. A. J., Iacomini M. 2006. A  $\alpha$ -glucan from the fruit bodies of edible mushrooms *Pleurotus eryngii* and *Pleurotus ostreatoroseus*. *Carbohydrate Polymers*, 66: 252–257.
- Czarnecki R., Grzybek J. 1995. Antiinflammatory and vasoprotective activities of polysaccharides isolated from fruit bodies of higher fungi. 1. Polysaccharides from *Trametes gibbosa* (Pers.: Fr) Fr (Polyporaceae). *Phytotherapy Research*, 9: 123–127.
- Cheung P. C. K. 2008. *Mushrooms As Functional Foods*. John Wiley & Sons, Inc. Hoboken, New Jersey. ISBN 978-0-470-05406-2.
- Chihara G., Hamuro J., Maeda Y., Arai Y., Fukuoka F. 1970. Fractionation and purification of the polysaccharides with marked antitumor activity, especially lentinan, from *Lentinus edodes* (Berk.) Sing. (an edible mushroom). *Cancer Research*, 30: 2776–2781.
- Cho S. M., Koshino H., Yu S. H., Yoo I. D. 1998. A manno-fucogalactan, fomitellan A, with mitogenic effect from fruit bodies of *Fomitella fraxinea* (Imaz.). *Carbohydrate Polymers*, 37: 13–18.
- Cho K. J., Chung K. S. 1999. Antitumor and antileukopenic activity of HCA, the protein-polysaccharide fraction of cultured mycelia of *Hebeloma crustuliniforme*. *Yakhak Hoeji*, 43: 629–634.
- Cho E. J., Oh J. Y., Chang H. Y., Yun J. W. 2006. Production of exopolysaccharides by submerged mycelial culture of a mushroom *Tremella fuciformis*. *Journal of Biotechnology*, 127: 129–140.
- Cui T., Chisti Y. 2003. Polysaccharopeptides of *Coriolus versicolor*: Physiological activity, uses, and production. *Biotechnology Advances*, 21: 109–122.
- Dong Q., Jia L. M., Fan J. N. 2006. A  $\beta$ -D-glucan isolated from the fruiting bodies of *Hericium erinaceus* and its aqueous conformation. *Carbohydrate Research*, 34: 1791–1795.
- Grzybek J., Zgorniak-Nowolsielska I., Kohlmunzer S. 1990. Antitumor and cytotoxic activity of tylophilan, a fungal polysaccharide from *Tylophilus felleus* fruit bodies. *Planta Medica*, 56: 670–671.
- Gutierrez A., Prieto A., Martinez A. T. 1996. Structural characterization of extra-cellular polysaccharides produced by fungi from the genus *Pleurotus*. *Carbohydrate Research*, 281: 143–154.
- Guterres Z., D., Mantovani M. S., da Eira A. F., Ribeiro L. R., Jordao B., Q. 2005. Genotoxic and antigeotoxic effects of organic extracts of mushroom *Agaricus blazei* Murril on V79 cells. *Genetics and Molecular Biology*, 28: 458–163.
- Han M. D., Jeong H., Lee J. W., Back S. J., Kim S. U., Yoon K. H. 1995. The composition and bioactivities of ganoderan by mycelial fractionation of *Ganoderma lucidum* IY009. *Korean Journal of Mycology*, 23: 285–297.
- Hawksworth D. L. 2001. Mushrooms: the extent of the unexplored potential. *International Journal of Medicinal Mushrooms*, 3: 333–340.
- Hobbs C. 1995. *Medicinal mushrooms: an exploration of tradition, healing, & culture*. 2nd edition. Santa Cruz CA, USA. *Botanica Press*. 252 pp. ISBN 1570671435.
- Hong J. H., Choi Y. H. 2007. Physico-chemical properties of protein-bound polysaccharide from *Agaricus blazei*

- Murill prepared by ultrafiltration and spray drying process. *International Journal of Food Science and Technology*, 42: 1–8.
- Hoshi H., Yagi Y., Iijima H., Matsunaga K., Ishihara Y., Yasuhara T. 2005. Isolation and characterization of a novel immunomodulatory  $\alpha$ -glucan-protein complex from the mycelium of *Tricholoma matsutake* in basidiomycetes. *Journal of Agricultural and Food Chemistry*, 53: 8948–8956.
- Jiang J. H., Slivova V., Harvey K., Valachovicova T., Sliva D. 2004. Ganoderma lucidum suppresses growth of breast cancer cells through the inhibition of Akt/NF-kappa B signaling. *Nutricion Cance an International Journal*, 49: 209–216.
- Kiho T., Katsuragawa M., Nagai K., Ukai S., Haga, M. 1992. Structure and anti-tumor activity of a linear (1 $\rightarrow$ 3)- $\beta$ -D-glucan from the alkaline extract of *Amanita muscaria*. *Carbohydrate Research*, 224: 237–243.
- Kim H. M., Han S. B., Oh G. T., Kim Y. H., Hong D. H., Hong N. D., Yoo I. D. 1996. Stimulation of humoral and cell mediated immunity by polysaccharide from mushroom *Phellinuslinteus*. *International Journal of Immunopharmacology*, 18: 295–303.
- Kim Y. O., Han S. B., Lee H. W., Ahn H. J., Yoon Y. D., Jung J. K., Kim H. M., Shin C. S. 2005. Immuno-stimulating effect of the endo-polysaccharide produced by submerged culture of *Inonotus obliquus*. *Life Sciences*, 77: 2438–2456.
- Kim G. Y., Lee J. Y., Lee, J. O., Ryu C. H., Choi B. T., Jeong Y. K., Lee K. W., Leong S. C., Cho Y. H. 2006. Partial characterization and immunostimulatory effect of a novel polysaccharide-protein complex extracted from *Phellinus linteus*. *Bioscience, Biotechnology, and Biochemistry*, 70: 1218–1226.
- Kishida E., Sone Y., Misaki A. 1989. Purification of an antitumor-active, branched (1 $\rightarrow$ 3)- $\beta$ -D-glucan from *Volvariella volvacea* and elucidation of its fine structure. *Carbohydrate Research*, 193: 227–239.
- Kobayashi H., Yoshida R., Kanada Y., Fukuda Y., Yagyu T., Inagaki K. et al. 2005. Suppressing effects of daily oral supplementation of beta-glucan extracted from *Agaricus blazei* Murill on spontaneous and peritoneal disseminated metastasis in mouse model. *Journal of Cancer Research and Clinical Oncology*, 131: 527–538.
- Kodama N., Komuta K., Sakai N., Nanba H. 2002. Effects of D-fraction, a polysaccharide from *Grifola frondosa* on tumor growth involve activation of NK cells. *Biological and Pharmaceutical Bulletin*, 25: 1647–1650.
- Konno S., Aynehchi S., Dolin D. J., Schwartz A. M., Choudhury M. S., Tazaki H. 2002. Anticancer and hypoglycemic effects of polysaccharides in edible and medicinal Maitake mushrooms (*Grifola frondosa*). *International Journal of Medicinal Mushrooms*, 4: 185–195.
- Lau C. B. S., Ho C. Y., Kim C. F., Leung K. N., Fung K. P., Tse T. F., Chan H. H. L., Chow M. S. S. 2004. Cytotoxic activities of *Coriolus versicolor* (Yunzhi) extract on human leukemia and lymphoma cells by induction of apoptosis. *Life Sciences*, 75: 797–808.
- Lavi I., Friesem D., Geresh S., Hadarb Y., Schwartz B. 2006. An aqueous polysaccharide extract from the edible mushroom *Pleurotus ostreatus* induces anti-proliferative and pro-apoptotic effects on HT-29 colon cancer cells. *Cancer Letters*, 244: 61–70.
- Lee S. S., Lee P. L., Chen C, F. Wang S. Y., Chen K. Y. 2003. Antitumor effects of polysaccharides of *Ganoderma lucidum* (Curt.: Fr.) P. Karst. (Ling Zhi, Reishi mushroom) (Aphyllphoromycetidae). *International Journal of Medicinal Mushrooms*, 5: 1–16.
- Lee H. J., Lee H. J., Lim E. S., Ahn K., S., Shim B. S., Kim H. M. et al. 2005. Cambodian *Phellinus linteus* inhibits experimental metastasis of melanoma cells in mice via regulation of urokinase type plasminogen activator. *Biological and Pharmaceutical Bulletin*, 28: 27–31.
- Leung M. Y. K., Liu C., Koon J. C. M., Fung K. P. 2006. Polysaccharide biological response modifier. *Immunology Letters*, 105: 101–114.
- Lim J. M., Joo J. H., Kim H. O., Kim H. M., Kim S. W., Hwang H. J., Yun J. W. 2005. Structural analysis and molecular characterization of exopolysaccharides produced by submerged mycelial culture of *Collybia maculata* TG1. *Carbohydrate Polymers*, 61: 296–303.
- Liu F., Ooi V. E. C., Liu W. K., Chang S. T. 1996. Immunomodulation and antitumor activity of polysaccharide-protein complex from the culture filtrates of a local edible mushroom *Tricholoma lobayense*. *General Pharmacology*, 27: 621–624.
- Misaki A., Kakuta M. 1995. Kikurage (tree-ear) and shirokikurage (white jelly-leaf) — *Auricularia auricula* and *Tremella fuciformis*. *Food Review International*, 11: 211–218.
- Mizuno T., Wasa T., Ito H., Suzuki C., Ukai N. 1992. Antitumor active polysaccharides isolated from the fruiting body of *Hericiumerinaceum*, an edible and medicinal mushroom called yamabushitake or houtou. *Bioscience, Biotechnology, and Biochemistry*, 56: 347–348.
- Mizuno T., Saito H., Nishitoba T., Kawagashi H. 1995. Antitumor active substances from mushrooms. *Food Reviews International*, 11: 23–61.
- Mizuno T., Zhuang C., Abe K., Okamoto H., Kiho T., Ukai N. S. L., Meijer L. 1999. Antitumor and hypoglycemic activities of polysaccharides from the sclerotia and mycelia of *Inonotus obliquus* (Pers.: Fr.) Pil. (Aphyllphoromycetidae). *International Journal of Medicinal Mushrooms*, 1: 301–316.

- Mordali M. F., Mostafavi H., Ghods S., Hedjaroude G. A. 2007. Immunomodulating and anticancer agents in realm of macromycetes fungi (macrofungi). *International Immunopharmacology*, 7: 701–724.
- Ogawa T., Kaburagi T. 1982. Glucan synthesis. 2. Synthesis of a branched D-glucotetraose, the repeating unit of the extracellular polysaccharides of *Grifola umbellata*, *Sclerotinia libertiana*, *Porodiscus pendulus* and *Schizophyllum commune* Fries. *Carbohydrate Research*, 103: 53–64.
- Ohno N., Miura N. N., Nakajima M., Yadomae T. 2000. Antitumor 1,3- $\alpha$ -glucan from cultured fruit body of *Sparassia scrispia*. *Biological and Pharmaceutical Bulletin*, 23: 866–872.
- Okazaki M., Adachi Y., Ohno N., Yadomae T. 1995. Structure-activity relationship of (1 $\rightarrow$ 3)- $\beta$ -D-glucans in the induction of cytokine production from macrophages, in vitro. *Biological and Pharmaceutical Bulletin*, 18: 1320–1327.
- Ooi V. E., Liu E. 2000. Immunomodulation and anticancer activity of polysaccharide-protein complexes. *Current Medicinal Chemistry*, 7: 715–729.
- Pacheco-Sanchez M., Boutin Y., Angers P., Gosselin A., Tweddell R. J. 2006. Abioactive (1 $\rightarrow$ 3)-, (1 $\rightarrow$ 4)- $\beta$ -D-glucan from *Collybia dryophila* and other mushrooms. *Mycologia*, 98: 180–185.
- Shida M., Sakai N. 2004. Heterogalactans obtained from some typical edible mushrooms. *Journal of the Japanese Society for Food Science and Technology-Nippon Shokuhin Kagaku Kogaku Kaishi*, 51: 559–562.
- Smiderle F. R., Carbonero E. R., Mellinger C. G., Sasaki G. L., Gorin, P. A. J., Iacomini M. 2006. Structural characterization of a polysaccharide and a  $\alpha$ -glucan isolated from the edible mushroom *Flammulina velutipes*. *Phytochemistry*, 67: 2189–2196.
- Surenjav U., Zhang L. N., Xu X. J., Zhang M., Cheung P. C. K., Zeng F. B. 2005. Structure, molecular weight and bioactivities of (1 $\rightarrow$ 3)- $\beta$ -D-glucans and its sulfate derivatives from four kinds of *Lentinus edodes*. *Chinese Journal of Polymer Science*, 23: 327–336.
- Surenjav U., Zhang L., Xu X., Zhang X., Zeng F. 2006. Effects of molecular structure on antitumor activities of (1 $\rightarrow$ 3)- $\beta$ -D-glucans from different *Lentinus edodes*. *Carbohydrate Polymers*, 63: 97–104.
- Tsukagoshi, S., Hashimoto, Y., Fujii, G., Kobayashi, H., Nomoto, K., and Orita, K. 1984. Krestin (Psk). *Cancer Treatment Reviews*, 11: 131–155.
- Ukawa Y., Ito H., Hisamatsu M. 2000. Antitumor effects of (1 $\rightarrow$ 3)- $\beta$ -D-glucan and (1 $\rightarrow$ 6)- $\beta$ -D-glucan purified from newly cultivated mushroom, Hatakeshimeji (*Lyophyllum decastes* Sing.). *Journal of Bioscience and Bioengineering*, 90: 98–104.
- Wang G. Y., Zhang J., Mizuno T., Zhuang C., Ito H., Mayuzumi H., Okamoto H., Li, J. 1993. Antitumor active polysaccharides from the Chinese mushroom Song-shan Lingzhi, the fruiting body of *Ganoderma tsugae*. *Bioscience, Biotechnology, and Biochemistry*, 57: 894–900.
- Wang Z. J., Luo D. H., Liang Z. Y. 2000. Structure of polysaccharides from the fruiting body of *Hericium erinaceus* Pers. *Carbohydrate Polymers*, 57: 241–247.
- Wasser S. P., Weis A. L. 1999. Medicinal Properties of Substances Occuring in Higher Basidiomycetes Mushrooms: Current Perspectives. *International Journal of Medicinal Mushrooms*, 1: 31–62.
- Wasser S. P. 2002. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. *Applied Microbiology and Biotechnology*, 60: 258–274.
- Wong S. M., Wong K. K., Chiu L. C. M., Cheung P. C. K. 2007. Non-starch polysaccharides from different developmental stages of *Pleurotus tuber-regium* inhibited the growth of human acute promyelocytic leukemia HL-60 cells by cell-cycle arrest and/or apoptotic induction. *Carbohydrate Polymers*, 68: 206–217.
- Yalin W., Ishurd O., Cuirong S., Yuanjiang P. 2005. Structure analysis and anti-tumor activity of ((1 $\rightarrow$ 3)- $\alpha$ -D-glucans (Cordyglucans) from the mycelia of *Cordyceps sinensis*. *Planta Medica*, 71: 381–384.
- Yoshida I., Kiho T., Usui S., Sakushima, M., Ukai S. 1996. Polysaccharides in fungi. 37. Immunomodulating activities of carboxymethylated derivatives of linear (1 $\rightarrow$ 3)- $\beta$ -D-glucans extracted from the fruiting bodies of *Agrocybe cylindracea* and *Amanita muscaria*. *Biological and Pharmaceutical Bulletin*, 19: 114–121.
- Zhang P., Cheung P. C. K. 2002. Evaluation of sulfated *Lentinus edodes*  $\alpha$ -(1 $\rightarrow$ 3)-D-glucan as a potential antitumor agent. *Bioscience, Biotechnology and Biochemistry*, 66: 1052–1056.
- Zhang Y., Mills G. L., Nair M. G. 2003. Cyclooxygenase inhibitory and antioxidant compounds from the fruiting body of an edible mushroom, *Agrocybe aegerita*. *Phytomedicine*, 10 (5): 386–90.
- Zhang M., Cui S. W., Cheung P. C. K., Wang Q. 2007. Polysaccharides from mushrooms: A review on their isolation process, structural characteristics and antitumor activity. *Trends in Food Science and Technology*, 18: 4–19.
- Zhuang C., Mizuno T., Shimada A., Ito H., Suzuki C., Mayuzumi Y., Okamoto H., Ma, Y., Li J. X. 1993. Antitumor protein-containing polysaccharides from a Chinese mushroom Fengweigu or Houbitake, *Pleurotus sajor-caju* (Fr) Sing. *Bioscience, Biotechnology and Biochemistry*, 57: 901–906.
- Zhuang, C., Mizuno, T., Ito, H., Shimura, K., Sumiya, T., Kawade M. 1994. Fractionation and antitumor-activity of polysaccharides from *Grifola frondosa* mycelium. *Bioscience, Biotechnology, and Biochemistry*, 58: 185–188.